Pankaj Puri1, Navjyot Kaur2, Sunny Pathania3, Sandeep Kumar4, P K Sharma5, V K Sashindran6. 1. Professor & Head, Department of Internal Medicine, Armed Forces Medical College, Pune 411040, India. 2. Assistant Professor (Medicine), Command Hospital (Southern Command), Pune 411040, India. 3. Resident, Department of Medicine, Armed Forces Medical College, Pune 411040, India. 4. Assistant Professor, Department of Medicine, Armed Forces Medical College, Pune 411040, India. 5. Associate Professor, Department of Medicine, Armed Forces Medical College, Pune 411040, India. 6. Professor & Head, Department of Geriatric Medicine, Armed Forces Medical College, Pune 411040, India.
Abstract
BACKGROUND: Both antitubercular therapy (ATT) and antiretroviral therapy (ART) can cause drug induced liver injury (DILI) in tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection. The aim of this research was to study ATT-induced liver function test (LFT) abnormalities in HIV-infected patients. METHODS: HIV-infected patients diagnosed with TB were evaluated with baseline LFT and CD4 counts. ATT regimen was modified if baseline LFT was significantly abnormal. Patients on protease inhibitors were given rifabutin instead of rifampicin. In patients on nevirapine-based ART, efavirenz was substituted for nevirapine. In ART-naive patients, the timing of introduction of ART was according to CD4 cell counts. LFT were repeated fortnightly or as clinically indicated for 10 weeks. RESULTS: We studied 100 patients with HIV ([M - 67, F - 23], mean age: 40.05 ± 10.75 years, mean CD4 cell count: 239.157 ± 228.49 cells/dL). Sixty-one patients were on ART prior to diagnosis of TB. Baseline LFT abnormalities (n = 40) were similar in ART and non-ART group (28/61 vs 12/39, p = 0.13). After starting ATT, derangement of LFT was observed in majority of patients (99/100). However, liver sparing ATT was required only in 15 patients. Bilirubin >2.5 mg/dL was seen only in 9 patients. Significant rise in transaminases was commoner in patients on concurrent ART and ATT (p = 0.044) and with baseline LFT abnormalities (p = 0.00016). There was no case of acute liver failure or mortality. CONCLUSION: Mild LFT abnormalities are common in HIV-infected individuals on ATT. Concomitant use of ATT and ART and baseline LFT abnormalities increase the risk of significant DILI. However, with closer follow-up, serious liver injury can be prevented.
BACKGROUND: Both antitubercular therapy (ATT) and antiretroviral therapy (ART) can cause drug induced liver injury (DILI) in tuberculosis (TB) and human immunodeficiency virus (HIV) coinfection. The aim of this research was to study ATT-induced liver function test (LFT) abnormalities in HIV-infectedpatients. METHODS:HIV-infectedpatients diagnosed with TB were evaluated with baseline LFT and CD4 counts. ATT regimen was modified if baseline LFT was significantly abnormal. Patients on protease inhibitors were given rifabutin instead of rifampicin. In patients on nevirapine-based ART, efavirenz was substituted for nevirapine. In ART-naive patients, the timing of introduction of ART was according to CD4 cell counts. LFT were repeated fortnightly or as clinically indicated for 10 weeks. RESULTS: We studied 100 patients with HIV ([M - 67, F - 23], mean age: 40.05 ± 10.75 years, mean CD4 cell count: 239.157 ± 228.49 cells/dL). Sixty-one patients were on ART prior to diagnosis of TB. Baseline LFT abnormalities (n = 40) were similar in ART and non-ART group (28/61 vs 12/39, p = 0.13). After starting ATT, derangement of LFT was observed in majority of patients (99/100). However, liver sparing ATT was required only in 15 patients. Bilirubin >2.5 mg/dL was seen only in 9 patients. Significant rise in transaminases was commoner in patients on concurrent ART and ATT (p = 0.044) and with baseline LFT abnormalities (p = 0.00016). There was no case of acute liver failure or mortality. CONCLUSION: Mild LFT abnormalities are common in HIV-infected individuals on ATT. Concomitant use of ATT and ART and baseline LFT abnormalities increase the risk of significant DILI. However, with closer follow-up, serious liver injury can be prevented.
Entities:
Keywords:
Antiretroviral therapy; Antitubercular therapy; Drug induced liver injury; HIV positive; Incidence
Authors: Vincent Soriano; Massimo Puoti; Pilar Garcia-Gascó; Juergen K Rockstroh; Yves Benhamou; Pablo Barreiro; Barbara McGovern Journal: AIDS Date: 2008-01-02 Impact factor: 4.177
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg Journal: N Engl J Med Date: 1998-03-26 Impact factor: 91.245
Authors: G P Aithal; P B Watkins; R J Andrade; D Larrey; M Molokhia; H Takikawa; C M Hunt; R A Wilke; M Avigan; N Kaplowitz; E Bjornsson; A K Daly Journal: Clin Pharmacol Ther Date: 2011-05-04 Impact factor: 6.875
Authors: Michael F Schneider; Stephen J Gange; Carolyn M Williams; Kathryn Anastos; Ruth M Greenblatt; Lawrence Kingsley; Roger Detels; Alvaro Muñoz Journal: AIDS Date: 2005-11-18 Impact factor: 4.177
Authors: Ronald B Reisler; Cong Han; William J Burman; Ellen M Tedaldi; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2003-12-01 Impact factor: 3.731
Authors: Mariana S Xavier; Anete Trajman; Carolina A S Schmaltz; Flavia M Sant'anna; Ivan R Maia; David J Hadad; Pedro Emmanuel A A do Brasil; Valeria Rolla Journal: Biomed Res Int Date: 2018-12-25 Impact factor: 3.411